Stay ahead of the curve with curated content from across the advanced therapies industry. From breaking news and regulatory updates to expert interviews and event highlights, Phacilitate’s Insights & Resources hub is your go-to destination for thought leadership in cell and gene therapy.
-
)
Despite the gloom, the data say otherwise: record UK raises and a string of $100M+ “mega deals” across AAV, mRNA, and cell therapy—many preclinical or Phase 1/2. The panel’s thesis: capital is availab ... -
)
Former Okon Therapeutics CEO Keren Leshem lays out how a contraceptive “ball” IUD became a uterine drug-delivery platform—and how the company lived through zero cash, founder exit, a product complaint ... -
)
Late-stage AAV success is less about bigger bioreactors and more about decisions that lock in supply, comparability, and cost. This session breaks down what teams overlook and how to plan for commerci ... -
)
The panel agrees the future is decentralized, hybrid, and data driven. Inline analytics, digital batch records, and AI will shorten cycles, cut costs, and widen access while QPs remain the final decis ... -
)
The room was full, the stats were sobering, and the advice was refreshingly actionable. Leaders from biotech, tech, and venture shared how to move beyond lip service to real inclusion: insist on balan ... -
)
This workshop laid out how biology, platforms, and policy can move genomic medicines from promising pilots to reliable patient access. The focus: stable AAV producer lines, modular ex vivo automation, ... -
)
The UK punches above its weight in advanced therapies: a dense concentration of developers, a single national health system, and regulators who understand ATMPs. The result is an ecosystem built for t ... -
)
Cell and gene therapies live or die on logistics. Time, temperature, and traceability must survive every handoff across sponsors, apheresis sites, CDMOs, depots, QPs, and clinics. This session focused ... -
)
The Nordic ecosystem leads in discovery and process innovation, supported by a public that embraces medical advances. Yet too many programs slow at the handoff from lab to clinic to market. This in-pe ... -
)
Mayra Battilani Becegato, former EMEA Commercial Strategy Director for Gene Therapy – Rare Diseases at Johnson & Johnson, shares her unconventional journey from finance to the front lines of advanced ... -
)
Barcelona is a thriving strategic hub for advanced therapies. At Advanced Therapies Europe 2025, the city becomes more than a location, it becomes a catalyst for collaboration, discovery, and growth. -
)
Get an exclusive first look at what’s in store for Advanced Therapies Europe 2025. This live webinar will explore the key themes, sessions, and standout experiences that will define this year’s event ... -
)
Marion Hitchcock, Managing Director of the Gene & Cell Therapies Incubator Berlin and R&D Strategy & Portfolio Manager at Bayer Pharmaceuticals, shares how a personal experience shaped her journey int ...